View More Recent Stories
-
BTIG Reiterates Neutral Rating on Procept BioRobotics Corp (PRCT)
-
PROCEPT BioRobotics Corporation (PRCT) Announces Proposed $175M Share Offering
-
PROCEPT BioRobotics Corporation (PRCT) November 70 and December 90 calls active as share price up 27%
-
PROCEPT BioRobotics Corporation (PRCT) Tops Q3 EPS by 9c
-
TD Cowen Reiterates Buy Rating on Procept BioRobotics Corp (PRCT)
-
Piper Sandler Reiterates Overweight Rating on Procept BioRobotics Corp (PRCT)
-
PROCEPT BioRobotics (PRCT) Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer
-
Procept BioRobotics Corp (PRCT) PT Raised to $99 at TD Cowen
-
Procept BioRobotics Corp (PRCT) PT Raised to $95 at Truist Securities
-
Procept BioRobotics Corp (PRCT) PT Raised to $94 at BofA Securities
-
TD Cowen Reiterates Buy Rating on Procept BioRobotics Corp (PRCT)
-
Truist Securities Reiterates Buy Rating on Procept BioRobotics Corp (PRCT)
-
PROCEPT BioRobotics Corporation (PRCT) Announces FDA Clearance of the HYDROS Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy
-
PROCEPT BioRobotics Corporation (PRCT) Tops Q2 EPS by 2c
-
PROCEPT BioRobotics Corporation (PRCT) August 55, 60 and 65 puts active
-
Procept BioRobotics Corp (PRCT) PT Raised to $79 at Truist Securities
-
TD Cowen Reiterates Buy Rating on Procept BioRobotics Corp (PRCT)
-
PROCEPT BioRobotics (PRCT) Announces New CPT Category I Code from the American Medical Association for Aquablation therapy
-
Analyst weighs in on current investor sentiment in MedTech sector
-
Top 4 AI robotics stocks set to soar (Part 3)

